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Context: Hepatitis C virus (HCV) infection is a public health problem. HCV alone is re-
sponsible for 90% cases of acute hepatitis among multiply transfused patients who are 
at risk of cirrhosis and hepatocellular carcinoma (HCC).
Objectives: To provide a clear picture of available data, we performed a systematic re-
view of the epidemiological characteristics of HCV infection among patients with in-
herited coagulation disorders in the countries under the Eastern Mediterranean Region 
Office (EMRO).
Evidence Acquisition: Meta-analysis was carried out on the basis of results of electronic 
and manual search. This analysis included studies in English, French, and Persian that 
met with the following criteria: (1) appropriate study design: cross-sectional, case-con-
trol, and cohort; (2) studies reporting HCV prevalence according to enzyme immune 
assay; (3) studies in which the sample population was enrolled from EMRO countries. 
According to the results of the heterogeneity tests, we used fixed-effect/random-effect 
model for our meta-analysis, with the “Metan” command. 
Results: We included 30 studies, most of which were from Iran. The mean age of the 
subjects ranged from 13 to 27.1 years. The majority of the patients were male (range, 81% 
to 100%). The pooled estimate of HCV infection among patients with inherited coagula-
tion disorders was 48.07% (95% confidence interval [CI], range: 27.39–55.68) in Iran, 36.03% 
(95% CI, range: 4.466–67.598) in Pakistan, and 48.27% (95% CI, range: 36.12–60.43) in all the 
EMRO countries taken together.
Conclusions: In Iran and other EMRO countries, the HCV infection rate among patients 
with inherited coagulation disorders is high. Our study shows that there is a lack of 
knowledge about infections in such patients in most of the EMRO countries. It is the 
responsibility of health-policy makers to address this knowledge gap and provide safe 
and adequate treatment for patients in high-risk groups.
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 Implication for health policy/practice/research/medical education:
This article is a collection of epidemiological studies on HCV in patients with inherited coagulation disorder in Iran and EMRO. 
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1. Context
Hepatitis C virus (HCV) infection is a common global 
public health problem (1, 2). Approximately 200 mil-
lion individuals are infected with HCV worldwide (3). 
Although the prevalence of HCV infections has reduced 
in developed countries because of effective prevention 
plans (4), it is still high in developing countries (5). HCV 
is considered as the main cause of liver diseases in both 
developed and developing countries and contributes to 
the increasing risk of liver failure and hepatocellular car-
cinoma (HCC) (3, 4, 6, 7). In addition, HCV is responsible 
for 20% of all acute hepatitis cases, 70% of all chronic hep-
atitis cases, 40% of all liver cirrhosis cases, 60% of HCCs, 
and 30% of infections in liver transplants in Europe (8, 9). 
Moreover, most of the recently admitted HCC patients 
had viral hepatitis C (10). Hemophilia is the most com-
mon inherited congenital bleeding disorder and it is esti-
mated to affect between 1 to 5 individuals per 50,000 male 
population (11). Hepatitis C is considered responsible for 
post-transfusion hepatitis and most of the observed liver 
diseases in treated hemophilia patients (12). All multiply 
transfused patients who received clotting-factor concen-
trates before 1985 and/or blood transfusions before 1992 
are infected with Hepatitis C, and almost all of them have 
tested positive for the HCV antibody. The prevalence of 
hepatitis C among hemophilic patients varies from 24% 
to 95% across countries (9, 13-18), and it is reported to 
range from 13.3% to 80.5% in Iran (19-21). Hepatitis C virus 
alone is responsible for 90% of acute hepatitis infections 
in these multiply transfused patients, and 60% to 80% of 
these infections progress to chronic hepatitis (22). 
2. Objectives
In the USA and European countries, prominent chang-
es have been observed in the epidemiology of hepatitis 
C (23, 24). We designed a literature review to determine 
epidemiological changes in the countries included in the 
Eastern Mediterranean Region Office of WHO (EMRO). For 
a clear and comprehensive presentation of the available 
data, we conducted a systematic review of the epidemio-
logical characteristics of hepatitis C to determine epi-
demiological changes in HCV infection among patients 
with inherited coagulation bleeding disorders in EMRO 
countries.
3. Evidence Acquisition
3.1. Search Strategy
We performed an electronic search of the available con-
tent and a manual search of specialty journals and con-
gress books to find all pertinent literature. We thought 
manual search was necessary because not all published 
data are available online. We began with an electronic 
search on the MEDLINE database Pubmed, Scopus, Ovid, 
Embase, and ISI. Then, we performed searches on Google 
Scholar and continued until the 200th link without 
finding any related article. We also performed Google 
searches to find gray literature. For Iranian articles, Per-
sian databases such as IranMedex, Scientific Information 
Database, and magIran were searched as we did it for all 
Iranian abstract books of the Iranian congresses. In addi-
tion, we searched all the related references in the articles 
found, and contacted some corresponding authors by e-
mail to obtain the full text of their article. We continued 
our search until it reached a saturation level and checked 
our search sensitivity by counting the duplications. We 
used terms such as “hemophilia” or “haemophilia” or 
“congenital inherited bleeding disease” and “hepatitis C” 
or “chronic hepatitis C” or “HCV,” the names of countries 
(Afghanistan, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, 
Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Pales-
tine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, 
United Arab Emirates, and Yemen), and Persian words as 
key words for Iran-specific searches. There were no limi-
tations in our search. We tried to include all published 
studies in the English, French, and Persian languages till 
the end of 2011.
3.2. Data Extraction and Quality Assessment
Data extraction was performed independently by 1 in-
vestigator (SH. AA), and critical appraisal for quality as-
sessment of the articles was performed with JAMA,form 
by who were not involved in the search (SM A). We coor-
dinated meetings before the critical appraisal and inves-
tigators have been justified about questions. After criti-
cal appraisal, selected articles were checked by both the 
authors.
3.3. Inclusion and Exclusion Criteria
Published/unpublished studies in English, French, and 
Persian were included if they met the following criteria: 
(1) studies with an appropriate design: cross-sectional 
(C-S), case-control (C-C), and cohort; (2) studies that re-
ported HCV prevalence as determined on the basis of the 
results of enzyme immune assays 3) studies in which the 
sample population was enrolled from EMRO countries. 
The exclusion criteria were as follows: (1) studies with 
probable errors and confusing data 2) studies in which 
only PCR findings were reported . Authors’ names or jour-
nal names did not influence our decision in excluding 
or including the articles. We extracted the first author’s 
name, the year of publication, name of the country, type 
of study, number of patients included in the study, pa-
tients’ characteristics such as mean age, male to female 
ratio, prevalence, and subgroup prevalence from the se-
lected studies, if full texts of the articles were available.
3.4. Statistical Analyses
We analyzed the extracted data to estimate the pooled 
prevalence of HCV infection and its 95% confidence inter-
val (CI) in Iran, Pakistan, Tunisia, and Iraq, and in all the 246 Hepat Mon. 2012;12(4)
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EMRO countries taken together. Statistical heterogeneity 
of the results was evaluated using heterogenicity tests, 
such as Q-squared test, I-squared test, and Tau-squared 
statistics. For Q-squared test, a P value of <0.1 was con-
sidered as significant. I-squared value lies between 0% 
to 100% and the heterogeneity increases with increasing 
I-squared value. Since not many articles were included, 
especially in our subgroups, we thought that the Tau-
squared test was more suitable for our study because it 
is not influenced by the number of included studies (25). 
Depending on the results of the heterogeneity tests, we 
used  a  fixed-effect/random-effect  model  for  our  meta-
analysis with the “Metan” command. The analysis was 
performed using Stata 11.  
4. Results
4.1. Search Result and Study Selection
Our findings showed that there are not enough data 
with respect to HCV infections among inherited coagu-
lation disorders from the developing countries of EMRO. 
Most of the EMRO countries did not report the number 
of hemophilic patients, and it varies from 1 per 100,000 
male population in Saudi Arabia and Pakistan to 15.8 per 
100,000 male population in Qatar (Table 1) (26). In addi-
tion, the available data are not up to date, and in most 
of the studies sample size is small and the quality of 
methodology poor. Through our searches of titles and 
abstracts, we found 39 potentially relevant studies that 
had evaluated anti-HCV seroprevalence in patients with 
inherited coagulation disorders in EMRO countries. All 
the studies were carefully evaluated to avoid including 
duplicates or low-quality papers. Two letters to editors 
(27, 28), and 1 review article were excluded (29). One study 
was excluded because of low sample size. (30) Another 
study was excluded because the full text was not available 
and there was not enough information in the abstract. 
Furthermore, we did not receive any response from the 
authors of the article after 1 month of our e-mail request 
for the full text (31). In addition, we excluded an article 
because of its selection bias and overestimation as it was 
reported previously (32), although there was enough 
data and an acceptable sample size (33). Three other stud-
ies were excluded because only PCR was performed to 
test for HCV infection (11, 34, 35). Finally, 30 studies were 
selected for the analysis (19-21, 36-62). It was noteworthy 
that no data was available from Egypt although this coun-
try has the highest number of  hemophilia patients (4141) 
in the eastern Meditarranean region (27). In addition, we 
could not find any relevant study on HCV prevalence in 
patients with bleeding disorder from Bahrain, Kuwait, 
Jordan, Lebanon, Libya, Oman, Qatar, Emirates, Yemen, 
Sudan, Djibouti, Syria, Morocco, Somali, and Afghanistan. 
Eventually, we found 21 studies from Iran involving 3171 of 
a total of 3463 hemophilic patients, which accounted for 
more than 90% of all hemophilic patients in this country; 
4 studies involving 841 subjects from Pakistan; 2 studies 
with 165 patients from Tunisia; 2 studies involving 290 
patients from Iraq; and only 1 study from Saudi Arabia. 
The mean age of the subjects ranged from 13 to 27.1 years. 
The majority of the study population was male (range, 
81% to 100%). Among the selected studies, 25 of them were 
C-S and the other 5 studies were C-C (Table 2). 
4.2. HCV Infection Among Iranian Hemophilic Patients
The seroprevalence of HCV infection among hemophil-
ic patients in Iran varies from 13.3% to 80.5% in point esti-
mation, and the pooled estimation according to the ran-
dom-effect model was 48.07% (95% CI, range: 35.66–60.48) 
with a P value of < 0.001 as determined by the Q-squared 
test, I2 = 98.6%, and Tau-square value = 816.8 (Figure 1). Fasa, 
in southern Iran, has an HCV infection rate of 13.3% in he-
mophilic patients, the lowest in Iran, and Isfahan, in the 
central region of Iran, has an HCV infection rate of 80.5% 
among patients with inherited coagulation disorders, 
the highest in Iran. We found that prevalence of HCV in-
fection among hemophilic patients is significantly lower 
in southern Iran than in northern and central Iran (Fig-
ure 2). 
4.3. HCV Infection Rate Among Hemophilia Patients in 
EMRO
The pooled estimate of HCV seroprevalence in hemo-
philic patients in the EMRO region was 48.27% ([95% 
CI, range: 36.12–60.43], P value as determined by the Q-
squared test ≤ 0.001, I2 value = 99.2%, and Tau-square 
value = 658.9) (Figure 3). The infection rate was 36.03% 
([95% CI, range: 4.46–67.59], P value as determined by the 
Q-squared test ≤ 0.001, I2 value = 99.2%, and Tau-square 
value = 1.0e + 03) in Pakistan, and it was estimated as 
55.70% ([95% CI: 48.1–63.27] with a P value as determined 
by the Q-squared test = 1.000, I2 value = 0.0%) for Tunisia 
by using the fixed-effect approach. The pooled estimate 
of HCV infection among hemophilic patients in Iraq was 
52.41% ([95% CI: 27.27–77.55] P value of Q-squared test was 
< 0.001, I2 test = 91.3%, and Tau-squared test = 301.4). The 
infection rate in Saudi Arabia is reported to be 78.6 % (95% 
CI: 63.4–93.8).
 Figure 4 shows the geographical distribution of individ-
ual or pooled estimates of the HCV infection rate among 
hemophilic patients in EMRO countries.
It seems that genotype 1a is the most common geno-
type among hemophilic patients; however, because of 
few reports from the different provinces of EMRO region, 
it was not possible to consider a pooled estimate of the 
prevalence of HCV infections. Most studies did not evalu-
ate the risk factors, but some have reported male sex, he-
mophilia A comparing with B, and the long duration of 
blood transfusion as risk factors although the odds ratio 
(OR) was not calculable because of the lack of sufficient 
number of studies.247 Hepat Mon. 2012;12(4)
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Iran Iraq Egypt Jordan Lebanon Morocco Pakistan Palestine Qatar Saudi-
Arabia
Sudan Tunisia
Mean 9.4 3.6 8.7 6.4 2.9 1.9 1.0 6.4 15.8 1.0 1.6 4.2
SD a 1.2 0.0 1.2 0.7 1.4 NR 0.5 1.9 NR 0.0 0.2 1.1
Table 1. Mean Hemophilia Prevalence (per 100000 male population) Determined From the Reported Number of Hemophilic Patients in EMRO Countries 
in the Period 1998–2006 Divided by Its Male Population in the Corresponding Period
a Abbreviation: SD; standard deviation
Author Date Design Sample Size ELISA Mean Age Male, % Prevalence, % 95% CI
Iran
Samar G 1996 C-S a 102 2nd 18.55 95 77.50 69.40–85.60
Ebrahim-Poor S 1997 C-C a 103 2nd NR a NR 76.7 68.54–84.86
Hashemiyeh M 1997 C-S 44 NR NR NR 81.8 70.39–93.20
Khamisipour GR 1999 C-S 31 NR 16 NR 41.9 24.53–59.27
Alavian SM 2001 C-S 176 2nd 20.65 86 60.20 52.97–67.43
Karimi M 2001 C-C 300 2nd NR NR 15.65 11.54–19.76
Karimi M 2002 C-S 310 2nd 17 90 15 11.03–18.97
Mansour-Ghanaei F 2002 C-S 101 2nd 19.7 99 71.30 62.48–80.12
Zahedi MJ 2004 C-S 97 NR 21.8 87 44.30 34.41–54.18
Ziaee M 2004 C-S 80 2nd 23 94 55 40.09–65.90
Sharifi-Mood B 2006 C-S 74 NR 13 84 32.00 21.37–42.63
Mohammad-Alizadeh 
AH
2006 C-S 66 3rd 24.6 83 59.10 47.23–70.96
Torabi SE 2006 C-S 162 NR 18.5 89 51.20 41.98–60.41
Javadzadeh-Shahsha-
hani H
2006 C-S 74 3rd 22.5 93 48.60 37.21–59.98
Sharifi-Mood B 2007 C-S 81 2nd NR NR 29.60 19.66–39.54
Samimi-Rad K 2007 C-S 76 3rd 20.1 87 43.40 32.26–54.54
Mojtabavi-Naini M 2007 C-S 553 2nd 23.4 84 22.60 19.11–26.09
Mahdaviani FS 2008 C-S 68 3rd 20.3 85 36.7 25.24–48.15
Mobini GR 2009 C-S 77 3rd 21.9 95 53.20 42.05–64.32
Hedayat B 2009 C-S 30 3rd NR NR 13.30 1.15–25.45
Kalantari H 2011 C-S 615 3rd 27.1 83 80.50 77.31–83.63 
Iraq
Al-Kubaisy WA 2006 C-S 47 3rd NR NR 66.00 52.46–79.54
Abdul-Karim ET 2011 C-S 243 NR 14.3 NR 40.30 34.13–46.47 
Pakistan
Raihan S 2010 C-C 408 3rd 17 81 1.40 0.26–2.54
Borhany M 2011 C-C 173 3rd NR 100 51.4 43.95–58.85
Naumaan M 2006 C-S 100 2nd & 
3rd
NR NR 56.00 46.27–65.73
Asif N 2009 C-S 161 NR NR NR 36.00 28.59–43.41
Saudi Arabia
Bahakim H 1991 C-C 28 NR NR NR 78.60 63.41–93.79
Tunisia
Langar. H 2005 C-S 70 NR 19 100 55.70 44.06–67.34
Djebbi A 2008 C-S 95 4th 19 100 55.70 45.71–65.69
 
Table 2. Characteristics of Studies and Patients in EMRO Countries
a Abbreviations: C-S, cross-sectional; C-C, case-control; NR, non-Reported; CI, confidence interval248 Hepat Mon. 2012;12(4)
Alavian SM et al. Big Gap of Knowledge About Hepatitis C Infection Rate
Figure 1. Summary of HCV Infection Rate Estimates in Hemophilic Patients in Iran
Figure 2. HCV Infection Rate Among Hemophilic Patients According to 3 Main Regions of Iran249 Hepat Mon. 2012;12(4)
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5. Discussion
Hepatitis C is a major health problem worldwide, and 
it leads to liver failure, other morbidities, and mortality 
among infected patients. Patients with inherited coagu-
lation disorders who have received multiple transfu-
sions are at high risk for hepatitis C infection, because 
HCV-infected blood or blood products are considered the 
primary sources of HCV transmission (6). Hemophilia is 
most common in Qatar, affecting 15.8 patients of each 
100,000 male population, but it is a neglected issue in 
neighboring countries, thus making it an important 
healthcare burden in these countries. The quality of life 
of hemophilic patients is similar to that of the general 
population in developed countries because of safety-
factor concentrates, blood transfusion, and a multidis-
Figure 3. Summary of HCV Infection Rate Estimates in Hemophilic Patients in EMRO Countries
Figure 4. Geographical Distribution of HCV Infection Among Hemophilic Patients in EMRO Countries250 Hepat Mon. 2012;12(4)
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ciplinary comprehensive care plan. However, in develop-
ing countries, because of the lack of safe blood products, 
treatment strategies, and registration centers for arrang-
ing necessary equipment, and possibly because of cost-
related problems, patients are at the risk of acquiring 
a disability. In addition, according to an estimation in 
a study, only 25% of all hemophilic patients receive ad-
equate treatment, and unfortunately most of them die 
before they reach the age of 20 years (42). Nevertheless, 
some developing countries in EMRO, like Iran, are mak-
ing efforts to ensure better care for patients (63). The in-
cidence of acute hepatitis C in hemophilic patients has 
reduced because of blood-product screening since the 
late 1980s and has reached a plateau in recent years (64). 
Although the situation of HCV infections in developing 
countries seems ambiguous, our findings indicate that 
HCV transmission by blood or blood products has been 
controlled successfully in Iran and perhaps in other de-
veloping countries in EMRO. The HCV infection rate has 
reached from 81.8% to 13.3% between 1997 and 2009 in Iran. 
Although laboratory assessment techniques have been 
developed and these are more sensitive than the tech-
niques used 13 years ago, the reason behind the increase 
in infection rate in 2011 is not clear. One of the reasons 
for this increase could be overestimation of values. This is 
a serious concern for health-policy makers, and they are 
responsible for identifying the reason for this augmen-
tation and resolve any possible problems. We found that 
HCV prevalence is significantly lower in southern Iran 
than in other parts of the country. Although the Sistan-
Baluchestan province in southern Iran has a high rate 
of HCV infection (0.449%) in general population, in the 
northern provinces of Golestan and Guilan, this infec-
tion is prevalent in more than 1% of the general popula-
tion (65). In addition, most of the immigrants to Tehran 
(capital of Iran) are from northern Iran, which may have 
led to an increase in the HCV-infection rate in central 
Iran. This reduction in HCV-infection rate can be con-
servatively considered as true for other EMRO countries 
as well; however, because of lack of sufficient data from 
most of these countries, this conclusion should be drawn 
with caution. HCV prevalence among hemophilic pa-
tients in Iran is higher than that in Pakistan. In contrast, 
the prevalence of hepatitis C among thalassemia patients 
in Iran is lower than that in any other EMRO country (66). 
We think that this difference indicates other sources of 
transmission in addition to blood transfusion, such as 
non-screened HCV-infected clotting factor concentrates 
and unsafe imported blood products. Contradictory re-
ports from Pakistan indicate a discrepancy in the correct 
evaluation of transmission reduction. Two recent (2010 
and 2011) studies from Pakistan have reported very differ-
ent rates of HCV infection among patients with bleeding 
disorder (1.4% versus 51.4%); this contradiction may be be-
cause of the dissimilarities between them in terms, bias 
in patient selection, type of transfused products, brand 
of blood-screening products, and laboratory assessment 
method. HCV screening is another issue overlooked in 
hemophilic patients. We found that most of the EMRO 
countries did not report the HCV prevalence among pa-
tients with inherited coagulation disorders, whereas ear-
ly diagnosis and treatment of these patients is required, 
because the response to treatment reduces with age (9). 
Moreover, the most common genotype among hemo-
philic patients is genotype 1 (67); treatment of patients 
with this genotype is considered difficult and requiring 
a longer duration than treatment of patients with other 
genotypes. Therefore, early diagnosis and treatment are 
really important in hemophilic patients (64).
We found that there is a huge lack of knowledge about 
patients with inherited coagulation disorders and the 
complications that they can encounter because of being 
at high risk for other conditions. Probably, other fields 
of medicine also face problems arising from such lack of 
knowledge. Other studies may confirm our hypothesis 
about developing countries in EMRO. Further studies are 
warranted for determining similar trends for other dis-
eases and identifying knowledge gaps for some forgotten 
diseases.
6. Conclusions
The HCV infection rate among patients with inherited 
coagulation disorders is high in Iran and other EMRO 
countries. It seems that the incidence of transmission 
of HCV infection through blood products has reduced 
in Iran. There is a lack of adequate data on hemophilic 
patients and the complications they may encounter in 
most of the EMRO countries. It is the responsibility of 
health-policy makers to address this knowledge gap and 
provide safe and adequate treatment for patients in high-
risk groups.
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